Pierre-Yves Dietrich
Geneva University Hospital, Switzerland
Posters & Accepted Abstracts: J Neurol Disord
Major advances have recently been achieved in cancer immunotherapy. Strategies launched decades ago, such as tumor antigenspecific therapeutic vaccines and adoptive transfer of tumor-infiltrating lymphocytes, are being complemented by molecular engineering approaches allowing the development of tumor-specific TCR transgenic and chimeric antigen receptor T cells. In addition, the spectacular results obtained in the last years with immune checkpoint inhibitors are transfiguring immunotherapy; these agents being used both as single molecules, but also in combination with other treatment modalities. Implementation of these various strategies is ongoing for more and more malignancies, including tumors located in the brain, raising the question of the immunological particularities of this site. This may necessitate cautious selection of tumor antigens, minimizing the immunosuppressive environment, and promoting efficient T cell trafficking to the tumor. Taking these aspects into account is critical to efficiently design immunotherapy for patients suffering from tumors located in the brain.
Neurological Disorders received 1343 citations as per Google Scholar report
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 